Eucrates Biomedical Acquisition Corp.
EUCR · NASDAQ
12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| % Growth | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 |
| % Margin | – | – | – |
| R&D Expenses | $0 | $0 | $0 |
| G&A Expenses | $0 | $743 | $0 |
| SG&A Expenses | $0 | $743 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 |
| Other Operating Expenses | $699 | $0 | $9 |
| Operating Expenses | $699 | $743 | $9 |
| Operating Income | -$699 | -$743 | $9 |
| % Margin | – | – | – |
| Other Income/Exp. Net | $3,118 | $4,567 | $0 |
| Pre-Tax Income | $2,420 | $3,824 | $9 |
| Tax Expense | -$3,118 | $0 | $0 |
| Net Income | $5,538 | $3,824 | $9 |
| % Margin | – | – | – |
| EPS | 1.86 | 1.28 | 0.001 |
| % Growth | 45.3% | 213,233.3% | – |
| EPS Diluted | 1.86 | 0.28 | 0.001 |
| Weighted Avg Shares Out | 2,979 | 2,979 | 13,459 |
| Weighted Avg Shares Out Dil | 2,979 | 13,459 | 13,459 |
| Supplemental Information | – | – | – |
| Interest Income | $701 | $36 | $0 |
| Interest Expense | $0 | $0 | $0 |
| Depreciation & Amortization | -$1,877 | -$4,532 | $206 |
| EBITDA | -$2,576 | -$5,275 | $9 |
| % Margin | – | – | – |